Tests a remote monitoring app for people with reduced-pumping heart failure
Tests a smartphone app that monitors adults with heart failure from home.
Plain-language title generated from the registry record
Registry title: Efficacy of Remote Monitoring of Patients With Heart Failure and Reduced Ejection Fraction by Using Caaring® Software
Key facts
- Where
- Ferrol and Palma de Mallorca, SpainSee the 2 sites
Where in Spain
- Complejo Hospitalario Universitario de FerrolFerrol, SpainNot yet recruiting
- Hospital Universitario de Son LlatzerPalma de Mallorca, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Persei Vivarium
- Trial code
- NCT06920160
- Record updated
- 4 June 2025
- Original description
The goal of this clinical trial investigation with device is to determinate the effectiveness of remote monitoring of patients with heart failure with reduced ejection fraction heart (EFS40%) using Caaring® software.Read full original descriptionShow less
Determination of the Efficacy of Remote Monitoring of Patients With Heart Failure and Reduced Ejection Fraction Using Caaring® Software
The goal of this clinical trial investigation with device is to determinate the effectiveness of remote monitoring of patients with heart failure with reduced ejection fraction heart (EFS40%) using Caaring® software.
The main question it aims to answer is if the development of a self-management platform (Caaring®) that enhances the role of the patient with heart failure in the course of their disease will reduce the number of re-entries. For this, researchers will compare the assessments between the two groups.
This is a randomized study with two arms. Online telemonitoring group: The follow-up of these patients will be carried out prospectively remotely through the Caaring® platform. And Prospective Control group: The data of these patients are collected prospectively for their routine medical visits for 12 weeks after their inclusion.
In addition, Control group patients must have clinical data from the 12 weeks after to their inclusion date available in the Medical Record, and/or through the monitoring platforms of the continuous monitoring devices.
Participants with heart failure will continue to receive conventional care and must have sufficient technological skills to use a smartphone.
Inclusion: Patients aged 18 years or older; Patients diagnosed with heart failure with reduced ejection fraction (EFS40%); Patients discharged after an episode of acute heart failure and/or patients who are being followed up after being admitted for heart failure; Patients who extensively use a smartphone; lnformed Consent is obtained from the patient.
Exclusion: Patients whose main diagnosis is a poorly controlled mental disorders ar other medical illness; Patients with terminal illness and/or in palliative care according to the criteria of the SECPAL (Spanish Society of Palliative Care); Patients with cognitive ar sensory difficulties or with insufficient command of Spanish who, in the opinion of the investigator, makes it difficult to understand the questions ar the scales, as long as they do not have a legally authorized representative capable of participating in the study; Transient patients in whom it may be anticipated that follow-up will not be completed due to a change of residence; Patients Who are participating at the time of recruitment in any other clinical trial. Participation in observational studies will not be an exclusion criteria; lnstitutionalized patients; Patients who are pregnant ar breastfeeding; Patients whose inclusion is not considered advisable by the investigator's assessment due to they are under specific follow-up in other hospital units (hemodialysis, transplants, etc.) that require mandatory hospital attendance less frequently than once every two months.